Sirnaomics
A Sino-American RNA therapeutics company developing innovative drugs for indications with unmet medical needs and large market opportunities.
Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead, Sirnaomics has established a drug candidate pipeline.
The company's lead candidate is STP122G, which represents the first drug candidate, which is in Phase I development as of Q1 2024.
Latest Sirnaomics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze